Daiichi Sankyo Company (4568-TO)

QUOTE AND NEWS
FiercePharma  Mar 23  Comment 
Times have been tough for Daiichi Sankyo, and they're about to get tougher for some of the Japanese company's U.S. staffers. The drugmaker is cutting its headquarters staff by 16% on Monday, with more layoffs expected in mid-April.
GenEng News  Mar 19  Comment 
Daiichi Sankyo will co-commercialize AstraZeneca’s Movantik™ (naloxegol) in the U.S., the companies said today, in an up-to-$825 million deal signed less than a month before the planned launch of the opioid-induced constipation (OIC) treatment...
Wall Street Journal  Mar 19  Comment 
AstraZeneca will partner with the U.S. unit of Daiichi Sankyo to launch constipation drug Movantik in the U.S. early next month, under a deal potentially valued at up to $825 million.
FiercePharma  Feb 9  Comment 
Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment Benicar set to lose patent protection next year. A black-box warning on its new drug Savaysa isn't helping matters. So analysts are wondering what the company can do to plug...
FiercePharma  Jan 9  Comment 
Japanese drugmaker Daiichi Sankyo will pay the $39 million to the state and federal health programs, and a whislteblower, to settle claims it paid doctors kickbacks to prescribe some of its drugs, Reuters reports.
FiercePharma  Jan 9  Comment 
What's long been a three-horse race just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter Savaysa. With the FDA's Thursday blessing, the drug will now face down a new-age anticoagulant trifecta that's been duking...
MedPage Today  Jan 9  Comment 
(MedPage Today) -- But agency limits use in Afib and VTE.
FierceBiotech  Jan 9  Comment 
The FDA signed off on Daiichi Sankyo's clot-preventing edoxaban, giving the Japanese drugmaker the green light to compete in a crowded market for next-generation anticoagulants.
Forbes  Oct 31  Comment 
On Thursday the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Daiichi Sankyo's edoxaban (Savaysa), but the outcome will likely result in a drug that will be on the market but that few physicians will...
FierceBiotech  Oct 30  Comment 
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.





You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki